263 related articles for article (PubMed ID: 29563616)
21. Up-Regulated Interleukin-10 Induced by E2F Transcription Factor 2-MicroRNA-17-5p Circuitry in Extrafollicular Effector B Cells Contributes to Autoantibody Production in Systemic Lupus Erythematosus.
Xu L; Wang L; Shi Y; Deng Y; Oates JC; Kamen DL; Gilkeson GS; Wang F; Zhang M; Tan W; Tsao BP
Arthritis Rheumatol; 2022 Mar; 74(3):496-507. PubMed ID: 34569195
[TBL] [Abstract][Full Text] [Related]
22. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia.
Slavikova M; Schmeisser H; Kontsekova E; Mateicka F; Borecky L; Kontsek P
J Interferon Cytokine Res; 2003 Mar; 23(3):143-7. PubMed ID: 12716486
[TBL] [Abstract][Full Text] [Related]
23. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies.
Hua J; Kirou K; Lee C; Crow MK
Arthritis Rheum; 2006 Jun; 54(6):1906-16. PubMed ID: 16736505
[TBL] [Abstract][Full Text] [Related]
24. NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production.
Yougbaré I; Boire G; Roy M; Lugnier C; Rouseau E
Can J Physiol Pharmacol; 2013 May; 91(5):353-61. PubMed ID: 23656347
[TBL] [Abstract][Full Text] [Related]
25. Mycophenolic acid inhibits SLE-associated cytokine expression and promotes apoptosis of peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Su DL; Wang HJ; Ji XH; Li YY; Xuan HB; Heng C; Li YF
Acta Pharmacol Sin; 2006 Aug; 27(8):1051-7. PubMed ID: 16867258
[TBL] [Abstract][Full Text] [Related]
26. Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility.
Aue A; Szelinski F; Weißenberg SY; Wiedemann A; Rose T; Lino AC; Dörner T
Rheumatology (Oxford); 2020 Nov; 59(11):3435-3442. PubMed ID: 32357246
[TBL] [Abstract][Full Text] [Related]
27. A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases.
Simon Q; Grasseau A; Boudigou M; Le Pottier L; Bettachioli E; Cornec D; Rouvière B; Jamin C; Le Lann L; ; ; Borghi MO; Aguilar-Quesada R; Renaudineau Y; Alarcón-Riquelme ME; Pers JO; Hillion S
Arthritis Rheumatol; 2021 Aug; 73(8):1550-1561. PubMed ID: 33605069
[TBL] [Abstract][Full Text] [Related]
28. Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus.
Morimoto AM; Flesher DT; Yang J; Wolslegel K; Wang X; Brady A; Abbas AR; Quarmby V; Wakshull E; Richardson B; Townsend MJ; Behrens TW
Arthritis Rheum; 2011 Aug; 63(8):2407-15. PubMed ID: 21506093
[TBL] [Abstract][Full Text] [Related]
29. Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons.
Stone RC; Feng D; Deng J; Singh S; Yang L; Fitzgerald-Bocarsly P; Eloranta ML; Rönnblom L; Barnes BJ
Arthritis Rheum; 2012 Mar; 64(3):788-98. PubMed ID: 21968701
[TBL] [Abstract][Full Text] [Related]
30. Type I interferon and T helper 17 cells co-exist and co-regulate disease pathogenesis in lupus patients.
Biswas PS; Aggarwal R; Levesque MC; Maers K; Ramani K
Int J Rheum Dis; 2015 Jul; 18(6):646-53. PubMed ID: 25960196
[TBL] [Abstract][Full Text] [Related]
31. Identification of Cyclin-Dependent Kinase 1 as a Novel Regulator of Type I Interferon Signaling in Systemic Lupus Erythematosus.
Wu L; Qin Y; Xia S; Dai M; Han X; Wu Y; Zhang X; Ma J; Wang Y; Tang Y; Liu Z; Zhu W; Jallal B; Yao Y; Qu B; Shen N
Arthritis Rheumatol; 2016 May; 68(5):1222-32. PubMed ID: 26663909
[TBL] [Abstract][Full Text] [Related]
32. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.
Munroe ME; Lu R; Zhao YD; Fife DA; Robertson JM; Guthridge JM; Niewold TB; Tsokos GC; Keith MP; Harley JB; James JA
Ann Rheum Dis; 2016 Nov; 75(11):2014-2021. PubMed ID: 27088255
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus.
Enocsson H; Wetterö J; Eloranta ML; Gullstrand B; Svanberg C; Larsson M; Bengtsson AA; Rönnblom L; Sjöwall C
Front Immunol; 2021; 12():688753. PubMed ID: 34276678
[TBL] [Abstract][Full Text] [Related]
34. Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha.
Habib HM; Taher TE; Isenberg DA; Mageed RA
Scand J Rheumatol; 2009; 38(2):112-20. PubMed ID: 19110660
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Type-I IFN subtype autoantibodies and activity in SLE serum and urine.
Harris BD; Kuruganti S; Deshpande A; Goepfert PA; Chatham WW; Walter MR
Lupus; 2020 Aug; 29(9):1095-1105. PubMed ID: 32611267
[TBL] [Abstract][Full Text] [Related]
36. Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus.
Cai Z; Wong CK; Kam NW; Dong J; Jiao D; Chu M; Lam CW; Tam LS
Lupus; 2015 Oct; 24(12):1257-66. PubMed ID: 25966926
[TBL] [Abstract][Full Text] [Related]
37. Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets.
Bradford HF; Haljasmägi L; Menon M; McDonnell TCR; Särekannu K; Vanker M; Peterson P; Wincup C; Abida R; Gonzalez RF; Bondet V; Duffy D; Isenberg DA; Kisand K; Mauri C
Cell Rep Med; 2023 Jan; 4(1):100894. PubMed ID: 36652906
[TBL] [Abstract][Full Text] [Related]
38. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity.
Sabry A; Sheashaa H; El-Husseini A; Mahmoud K; Eldahshan KF; George SK; Abdel-Khalek E; El-Shafey EM; Abo-Zenah H
Cytokine; 2006 Aug; 35(3-4):148-53. PubMed ID: 17027280
[TBL] [Abstract][Full Text] [Related]
39. Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro.
Wirestam L; Enocsson H; Skogh T; Eloranta ML; Rönnblom L; Sjöwall C; Wetterö J
Clin Exp Immunol; 2017 Jul; 189(1):83-91. PubMed ID: 28257596
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells.
Nakou M; Papadimitraki ED; Fanouriakis A; Bertsias GK; Choulaki C; Goulidaki N; Sidiropoulos P; Boumpas DT
Clin Exp Rheumatol; 2013; 31(2):172-9. PubMed ID: 23137515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
